JP2022551813A - 麻疹に対する併用抗ウイルス療法 - Google Patents

麻疹に対する併用抗ウイルス療法 Download PDF

Info

Publication number
JP2022551813A
JP2022551813A JP2022515099A JP2022515099A JP2022551813A JP 2022551813 A JP2022551813 A JP 2022551813A JP 2022515099 A JP2022515099 A JP 2022515099A JP 2022515099 A JP2022515099 A JP 2022515099A JP 2022551813 A JP2022551813 A JP 2022551813A
Authority
JP
Japan
Prior art keywords
peptide
hrc
fip
antiviral
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022515099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551813A5 (https=
JPWO2021046398A5 (https=
Inventor
ポロット、マッテオ
モスコーナ、アン
アラビ、クリストファー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of JP2022551813A publication Critical patent/JP2022551813A/ja
Publication of JP2022551813A5 publication Critical patent/JP2022551813A5/ja
Publication of JPWO2021046398A5 publication Critical patent/JPWO2021046398A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18433—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022515099A 2019-09-04 2020-09-04 麻疹に対する併用抗ウイルス療法 Pending JP2022551813A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962895752P 2019-09-04 2019-09-04
US62/895,752 2019-09-04
US202062988286P 2020-03-11 2020-03-11
US62/988,286 2020-03-11
US202063009883P 2020-04-14 2020-04-14
US63/009,883 2020-04-14
PCT/US2020/049473 WO2021046398A2 (en) 2019-09-04 2020-09-04 Combination antiviral therapy for measles

Publications (3)

Publication Number Publication Date
JP2022551813A true JP2022551813A (ja) 2022-12-14
JP2022551813A5 JP2022551813A5 (https=) 2023-09-13
JPWO2021046398A5 JPWO2021046398A5 (https=) 2023-09-13

Family

ID=74853434

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022515099A Pending JP2022551813A (ja) 2019-09-04 2020-09-04 麻疹に対する併用抗ウイルス療法

Country Status (6)

Country Link
US (1) US20230014151A1 (https=)
EP (1) EP4025586A4 (https=)
JP (1) JP2022551813A (https=)
CN (1) CN114729007A (https=)
IL (1) IL291091A (https=)
WO (1) WO2021046398A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159372A1 (en) * 2021-01-22 2022-07-28 Decoy Therapeutics, Inc. Methods and compositions for treating infections
WO2023150375A2 (en) * 2022-02-07 2023-08-10 Decoy Therapeutics Inc. Methods and compositions for treating covid infections
WO2025085916A1 (en) * 2023-10-20 2025-04-24 The Trustees Of Columbia University In The City Of New York Humanized monoclonal antibody and vaccines against measles virus
WO2025111546A1 (en) * 2023-11-22 2025-05-30 Board Of Trustees Of Michigan State University Development of broad-spectrum anti-opioid vaccines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010527376A (ja) * 2007-05-16 2010-08-12 コンジュケム バイオテクノロジーズ インコーポレイテッド 抗ウイルスペプチドのシステイン酸誘導体
WO2015171924A2 (en) * 2014-05-07 2015-11-12 Cornell University Inhibitors of fusion between viral and cell membranes as well as compositions and methods of using them

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1692265T3 (da) * 2003-11-04 2011-11-21 Univ Tulane Fremgangsmåde til hindring af en virus-celle-fusion ved hæmning af fusionsinitieringsområdets funktion i RNA-vira med klasse 1-membranfusogene envelopeproteiner
WO2012020108A2 (en) * 2010-08-11 2012-02-16 Cormus Srl Multimeric inhibitors of viral fusion and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010527376A (ja) * 2007-05-16 2010-08-12 コンジュケム バイオテクノロジーズ インコーポレイテッド 抗ウイルスペプチドのシステイン酸誘導体
WO2015171924A2 (en) * 2014-05-07 2015-11-12 Cornell University Inhibitors of fusion between viral and cell membranes as well as compositions and methods of using them

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE: GENPEPT, [ONLINE]: "DEFINITION: fusion protein [Measles morbillivirus]", ACCESSION: NP_056922, JPN6024032359, 13 August 2018 (2018-08-13), ISSN: 0005552368 *
FIGUEIRA, T. N. ET AL.: ""Structure-Stability-Function Mechanistic Links in the Anti-Measles Virus Action of Tocopherol-Deriv", ACS NANO, vol. 12, JPN6024032357, 2018, pages 9855 - 9865, XP093100901, ISSN: 0005552366, DOI: 10.1021/acsnano.8b01422 *
RICHARDSON, C. D. ET AL.: ""Specific inhibition of paramyxovirus and myxovirus replication by oligopeptides with amino acid seq", VIROLOGY, vol. 105, JPN6024032358, 1980, pages 205 - 222, XP023048638, ISSN: 0005552367, DOI: 10.1016/0042-6822(80)90168-3 *

Also Published As

Publication number Publication date
WO2021046398A2 (en) 2021-03-11
US20230014151A1 (en) 2023-01-19
CN114729007A (zh) 2022-07-08
EP4025586A4 (en) 2024-01-03
IL291091A (en) 2022-05-01
WO2021046398A3 (en) 2021-04-08
EP4025586A2 (en) 2022-07-13

Similar Documents

Publication Publication Date Title
JP2022551813A (ja) 麻疹に対する併用抗ウイルス療法
Liebert et al. Antigenic determinants of measles virus hemagglutinin associated with neurovirulence
US20240400651A1 (en) Neutralizing monoclonal antibodies against covid-19
JP2019193662A (ja) 弱毒化ニューカッスル病ウイルスを特徴とする組成物並びに新生物を治療するための使用方法
Mathieu et al. Molecular features of the measles virus viral fusion complex that favor infection and spread in the brain
WO2021257512A1 (en) Humanized ace2-fc fusion protein for treatment and prevention of sars-cov-2 infection
US20170342134A1 (en) Rsv g protein specific antibodies
JP2024020214A (ja) キメラベクター
Song et al. A new mechanism of respiratory syncytial virus entry inhibition by small-molecule to overcome K394R-associated resistance
US20110305670A1 (en) Nucleic acid encoding fusion polypeptides that prevent or inhibit hiv infection
US20240398911A1 (en) Engineered receptors and monoclonal antibodies for cronaviruses and uses thereof
Kong et al. Inhibition of virus-like particle release of Sendai virus and Nipah virus, but not that of mumps virus, by tetherin/CD317/BST-2
EP2096121A1 (en) Antiviral peptides comprising lipid attachment signals and methods of use
JP2004504274A (ja) インターフェロン（ＩＦＮ）応答に拮抗する（ａｎｔａｇｏｎｉｚｉｎｇ）肺炎ウイルスＮＳタンパク質
JP2023540705A (ja) 修飾された抗ウイルス結合剤
US20050048030A1 (en) Paramyxoviruses as gene transfer vectors to lung cells
KR20230129370A (ko) 코로나 바이러스 교차반응 항체의 확인 방법
Khasawneh et al. Forced virus evolution reveals functional crosstalk between the disulfide bonded region and membrane proximal ectodomain region of HIV-1 gp41
WO2022159842A1 (en) Antibody combination therapies for sars-cov-2 infection
US11186626B2 (en) Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop
US20250375514A1 (en) Methods of inhibiting paramyxoviridae fusion to a target cell
WO2025085916A1 (en) Humanized monoclonal antibody and vaccines against measles virus
US20250263442A1 (en) Recombinant cedar virus chimeras
Reuter et al. SARS-CoV-2 Spike Protein Is Capable of Inducing Cell-Cell Fusions Independent from Its Receptor ACE2 and This Activity Can Be Impaired by Furin Inhibitors or a Subset of Monoclonal Antibodies. Viruses. 2023; 15 (7): 1500
Hicks Identification and Characterization of Essential Residues at the Apex of the RSV Fusion Protein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250318